TABLE 1

Clinical interpretation of the rapid test for tuberculosis “GenoType MTBDRsl V2 (Hain Lifescience)”

DrugFailing WT bandDeveloping mutation bandMutationClassification: final BCVsFinal interpretation for clinicians
OFX-LFXMFXAMCMKM
OFX
LFX
MFX
gyrA WT1-
-
G88A
G88C
High
High
Indet
High#
No OFX-LFX use, not informative for MFX
No OFX-LFX use, not informative for MFX
gyrA WT2gyrA MUT1
gyrA MUT2
A90V
S91P
High
High
High
High
No OFX-LFX use, higher dosage of MFX?
No OFX-LFX use, higher dosage of MFX?
gyrA WT3gyrA MUT3A
gyrA MUT3B
-
gyrA MUT3C
gyrA MUT3D
D94A
D94N
D94Y
D94G
D94H
High
High
High
High
High
High
High
High
High
Indet
No OFX-LFX use, higher dosage of MFX?
No use of fluoroquinolones
No OFX-LFX use, higher dosage of MFX?
No use of fluoroquinolones
No OFX-LFX use, not informative for MFX
gyrB WTgyrB MUT1
gyrB MUT2
N538D
E540V+
Indet
Indet
Indet
Indet
Not informative
Not informative
AM
CM
KM
rrs WT1rrs MUT1
-
a1401g
c1402t
High
Indet
High
High
High
High#
No use of second-line injectables
No CM use, not informative for AM- KM
rrs WT2rrs MUT2g1484tHighHighHigh#No AM-CM use, not informative for KM
KMeis WT1-g-37tMinimal#Not informative
eis WT2eis MUT1
-
-
c-14t
c-12t
g-10a
High
Minimal#
High
No use of kanamycin
Not informative
No use of kanamycin
eis WT3-c-2aIndetNot informative

Modified from [13]. OFX: ofloxacin; LFX: levofloxacin; MFX: moxifloxacin, AM: amikacin; CM: capreomycin; KM: kanamycin; BCVs: best confidence values; Indet: indeterminate. #: the association of these mutation is based on nominal p-values only (putative, not corrected; refer to Miotto et al. [13]); : N499D; +: E501V.